In the last trading session, 1.65 million shares of the Apellis Pharmaceuticals Inc (NASDAQ:APLS) were traded, and its beta was 0.87. Most recently the company’s share price was $27.40, and it changed around -$0.05 or -0.18% from the last close, which brings the market valuation of the company to $3.34B. APLS currently trades at a discount to its 52-week high of $73.80, offering almost -169.34% off that amount. The share price’s 52-week low was $26.69, which indicates that the current value has risen by an impressive 2.59% since then. We note from Apellis Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 3.85 million shares, with the 3-month average coming to 1.90 million.
Apellis Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.53. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended APLS as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Apellis Pharmaceuticals Inc is expected to report earnings per share of -0.29 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Instantly APLS has showed a red trend with a performance of -0.18% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 29.50 on recent trading dayincreased the stock’s daily price by 7.12%. The company’s shares are currently down -54.23% year-to-date, but still down -1.23% over the last five days. On the other hand, Apellis Pharmaceuticals Inc (NASDAQ:APLS) is -31.40% down in the 30-day period. We can see from the shorts that 15.28 million shares have been sold at a short interest cover period of 13.93 day(s).
The consensus price target as assigned by Wall Street analysts is $78.5, which translates to bulls needing to increase their stock price by 65.1% from its current value. Analyst projections state that APLS is forecast to be at a low of $39 and a high of $113.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Apellis Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -50.29 percent over the past six months and at a 69.21% annual growth rate that is well above the industry average of 17.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 75.20% in revenue this quarter, and will report an increase of 75.30% in the next quarter. The year-over-year growth rate is expected to be 98.60%, up from the previous year.
Consensus estimates provided by 17 financial analysts predict the company will bring in an average of 200.84M in revenue for the current quarter. 17 analysts expect Apellis Pharmaceuticals Inc to make 214.86M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 110.4M and 146.38M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 81.90%. Forecasts for the next quarter put sales growth at 46.80%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.70%. Apellis Pharmaceuticals Inc earnings are expected to increase by 71.84% in 2024, but the outlook is positive 33.30% per year for the next five years.
APLS Dividends
Apellis Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in November.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 14.28% of Apellis Pharmaceuticals Inc shares, and 97.25% of them are in the hands of institutional investors. The stock currently has a share float of 113.45%. Apellis Pharmaceuticals Inc stock is held by 377.0 institutions, with WELLINGTON MANAGEMENT GROUP LLP being the largest institutional investor. By 2024-06-30, it held 13.3288% of the shares, which is about 16.39 million shares worth $628.67 million.
ECOR1 CAPITAL, LLC, with 9.3681% or 11.61 million shares worth $445.26 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
